Company Filing History:
Years Active: 2023
Title: David Feltquate: Innovator in Cancer Treatment
Introduction
David Feltquate is a notable inventor based in Belle Mead, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on combining therapies to enhance the effectiveness of cancer treatments.
Latest Patents
David Feltquate holds a patent for a groundbreaking method titled "Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer." This patent outlines methods for the clinical treatment of tumors, particularly advanced solid tumors, in patients with specific levels of serum IL-8. The combination of an anti-IL-8 antibody with an anti-PD-1 antibody represents a promising approach to improving patient outcomes in cancer therapy. He has 1 patent to his name.
Career Highlights
David is currently employed at Bristol-Myers Squibb Company, a leading biopharmaceutical company known for its innovative treatments. His role involves extensive research and collaboration with other experts in the field to develop effective cancer therapies.
Collaborations
Throughout his career, David has worked alongside talented colleagues, including Michael Carleton and Olivier De Henau. Their collaborative efforts contribute to the advancement of cancer treatment methodologies.
Conclusion
David Feltquate's innovative work in cancer treatment exemplifies the impact of combining therapies to enhance patient care. His contributions to the field are invaluable and continue to inspire advancements in medical research.